FOLH1 and posterior cortical atrophy: As early as 1994, a murine monoclonal 111Indium(111In)-labeled IgG antibody against PSMA (111In-capromab pendetide; ProstaScint®, Cytogen Corporation, Princeton, NJ, USA) was successfully evaluated in PCa patients and approved by the FDA [2]; however, this diagnostic approach failed to gain acceptance—mainly due to the very slow kinetics/blood clearance of complete IgG antibodies resulting in a poor target/background ratio, as well as the low spatial resolution of 111In.